Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 BlockadeOA
Objective:Liposomal doxorubicin(L-DOX)may alter macrophage-mediated immune regulation in triple-negative breast cancer(TNBC),but its role in programmed death-ligand 1(PD-L1)-associated immune escape remains unclear.This study aimed to determine whether L-DOX induces a macrophage-centered PD-L1 response and affects the efficacy of PD-L1 blockade in TNBC.Methods:Public bulk and single-cell transcriptomic datasets,bone marrow-derived macrophage models,CD8+T-cell co-culture assays,promoter-binding analyses,and syngeneic EO771 and 4T1 TNBC mouse models were used to examine PD-L1 regulation and immune function after L-DOX treatment.Results:The principal findings were that L-DOX preferentially induced a PD-L1-high macrophage state and sensitized TNBC tumors to PD-L1 blockade.DOX-containing therapy was associated with PD-L1 upregulation enriched in tumor-associated macrophages,and L-DOX induced stronger macrophage PD-L1 expression than free DOX or taxane-based agents.Mechanistically,L-DOX accumulation triggered DNA damage-associated ATM-p53 and cGAS-STING signaling,leading to RELA/p65-dependent NF-κB activation and PD-L1 transcription.Functionally,L-DOX-conditioned macrophages suppressed CD8^(+)T-cell activation,proliferation,and tumor-cell killing,whereas PD-L1 blockade restored CD8^(+)effector function,promoted pro-inflammatory macrophage features,and improved tumor control in EO771 and 4T1 models compared with either monotherapy.Conclusion:L-DOX induces a PD-L1-high macrophage state with immunosuppressive features that constrains antitumor T-cell responses.Combining L-DOX with PD-L1 blockade may provide a rational chemoimmunotherapy strategy for TNBC.
Yu Zheng;Peng Zheng;Yidan Zheng;Zihan Xi;Tao Huang
Department of Breast and Thyroid Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,ChinaDepartment of Thyroid Surgery,Fujian Medical University Union Hospital,Fuzhou,ChinaDepartment of Cardiovascular Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,ChinaDepartment of Breast and Thyroid Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,ChinaDepartment of Breast and Thyroid Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China
医药卫生
Liposomal doxorubicintumor-associated macrophagesprogrammed death-ligand 1(PD-L1)triplenegative breast cancerneoadjuvant chemotherapy
《Oncology Research》 2026 (10)
P.740-766,27
supported by the Key Program of the Natural Science Foundation of Hubei Province(Grant No.2021BCA142 to Tao Huang)the National Natural Science Foundation of China(Grant No.82503923 to Zihan Xi).
评论